Stereotactic hypofractionated high-dose irradiation for stage I nonsmall cell lung carcinoma: clinical outcomes in 245 subjects in a Japanese multiinstitutional study

Cancer
Hiroshi OnishiKazunari Yamada

Abstract

Stereotactic irradiation (STI) has been actively performed using various methods to achieve better local control of Stage I nonsmall cell lung carcinoma (NSCLC) in Japan. The authors retrospectively evaluated results from a Japanese multiinstitutional study. Patients with Stage I NSCLC (n = 245; median age, 76 years; T1N0M0, n = 155; T2N0M0, n = 90) were treated with hypofractionated high-dose STI in 13 institutions. Stereotactic three-dimensional treatment was performed using noncoplanar dynamic arcs or multiple static ports. A total dose of 18-75 gray (Gy) at the isocenter was administered in 1-22 fractions. The median calculated biologic effective dose (BED) was 108 Gy (range, 57-180 Gy). During follow-up (median, 24 months; range, 7-78 months), pulmonary complications of National Cancer Institute-Common Toxicity Criteria Grade > 2 were observed in only 6 patients (2.4%). Local progression occurred in 33 patients (14.5%), and the local recurrence rate was 8.1% for BED > or = 100 Gy compared with 26.4% for < 100 Gy (P < 0.05). The 3-year overall survival rate of medically operable patients was 88.4% for BED > or = 100 Gy compared with 69.4% for < 100 Gy (P < 0.05). Hypofractionated high-dose STI with BED < 150 Gy was feasible...Continue Reading

References

Jun 1, 1991·International Journal of Radiation Oncology, Biology, Physics·R J YaesY Maruyama
Jan 1, 1995·The Journal of Thoracic and Cardiovascular Surgery·N MartiniR J Ginsberg
Jan 15, 1995·International Journal of Radiation Oncology, Biology, Physics·P H GrahamA O Langlands
Oct 20, 1993·International Journal of Radiation Oncology, Biology, Physics·L KaskowitzC Rush
Jan 15, 1996·International Journal of Radiation Oncology, Biology, Physics·A D KrolJ W Leer
Oct 1, 1996·International Journal of Radiation Oncology, Biology, Physics·P A KupelianP Allen
Mar 15, 1997·International Journal of Radiation Oncology, Biology, Physics·J M RobertsonA S Lichter
Jan 9, 1998·International Journal of Radiation Oncology, Biology, Physics·G S SibleyL R Prosnitz
Apr 28, 1999·Lancet·H ShiratoK Miyasaka
Feb 5, 2000·Seminars in Surgical Oncology·C F Mountain
Feb 5, 2000·Seminars in Surgical Oncology·G L Zorn, J C Nesbitt
Oct 6, 2000·International Journal of Radiation Oncology, Biology, Physics·P C CheungS Zhou
Feb 13, 2001·International Journal of Radiation Oncology, Biology, Physics·M MehtaJ Fowler
Oct 13, 2001·International Journal of Radiation Oncology, Biology, Physics·M UematsuS Kusano
Apr 18, 2002·International Journal of Radiation Oncology, Biology, Physics·Yasushi NagataMasahiro Hiraoka
May 10, 2003·International Journal of Radiation Oncology, Biology, Physics·Holger HofJürgen Debus J
Jun 27, 2003·Lung Cancer : Journal of the International Association for the Study of Lung Cancer·Xueying QiaoRolf Lewensohn

❮ Previous
Next ❯

Citations

Dec 22, 2005·International Journal of Clinical Oncology·Takuhito TadaYuichi Inoue
Mar 2, 2006·International Journal of Clinical Oncology·Tatsuo OhiraHarubumi Kato
Jul 20, 2006·International Journal of Clinical Oncology·Eriko TokunagaYoshihiko Maehara
Mar 24, 2007·International Journal of Clinical Oncology·Yasushi NagataMasahiro Hiraoka
Mar 16, 2012·General Thoracic and Cardiovascular Surgery·Satoshi Ishikura
Sep 13, 2007·Nature Clinical Practice. Oncology·David Ball, H Rodney Withers
Dec 10, 2009·Nature Reviews. Clinical Oncology·Simon S LoRobert D Timmerman
Jun 29, 2010·Annals of Oncology : Official Journal of the European Society for Medical Oncology·L CrinòUNKNOWN ESMO Guidelines Working Group
Feb 26, 2013·Japanese Journal of Clinical Oncology·Hiroshi Onishi, Tsutomu Araki
Sep 7, 2012·Journal of Radiation Research·Hideharu MiuraToshihiko Inoue
Jan 6, 2006·The Cancer Journal·Loren K Mell, Arno J Mundt
Apr 15, 2006·The Cancer Journal·Robert D Timmerman, Michael Story
Nov 26, 2010·Current Opinion in Oncology·David Palma, Suresh Senan
Jun 22, 2010·American Journal of Clinical Oncology·Ehatsham AhmadStephen Seagren
Apr 28, 2007·The Cancer Journal·Malcolm V BrockStephen B Baylin
Sep 1, 2007·The Cancer Journal·Sonal SuraKenneth E Rosenzweig
Jan 26, 2011·The Cancer Journal·John H HeinzerlingRobert D Timmerman
May 28, 2013·The Cancer Journal·Terence M Williams, Adam Maier
Oct 26, 2010·Journal of Hematology & Oncology·Keith UngerBrian T Collins
Sep 3, 2009·Cell Structure and Function·Kaori TsutsumiYusuke Ohba
Sep 5, 2006·Cell Structure and Function·Kaori TsutsumiTakeshi Nishioka
Nov 19, 2013·PLoS Computational Biology·Harald KempfMichael Meyer-Hermann

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.